Varicella zoster virus envelope glycoprotein e
As of the edition of 20 October 2026, Varicella zoster virus envelope glycoprotein e is a vaccine component: marketed, first approved in 2017 (US); US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Vaccine component
- Brand name
- Shingrix
- First approved
- 20 October 2017 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- GSK
- Registered trials
- 51, 2 stopped early
- Disease areas
- Infections; Immune system; Nervous system; Skin and connective tissue; Blood and lymph; Cancer
US protection
US protection ends in 2029.
US protection ends in 2029, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by GSK. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 1 |
| Phase 1 | 5 | 3 | 1 | 0 |
| Phase 2 | 10 | 6 | 4 | 0 |
| Phase 3 | 23 | 21 | 1 | 0 |
| Phase 4 | 11 | 0 | 9 | 1 |
| All trials | 51 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2007 to now |